DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/17878146
Sources: http://www.ncbi.nlm.nih.gov/pubmed/17878146
Polymyxin B is a lipopeptide antibiotic isolated from Bacillus polymyxa. Its basic structure consists of a polycationic peptide ring and a tripeptide side chain with a fatty acid tail. Polymyxin B is a mixture of at least four closely related components, polymyxin B1 to B4, with polymyxin B1 and B2 being the two major components. Polymyxin B acts on Gram-negative bacteria by interacting with lipopolysaccharide (LPS) of the outer membrane and destabilizing it. Polymyxin B is indicated for the treatment of many bacterial diseases such as meningeal infections, urinary tract infections and bacteremia.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/19202043
Curator's Comment: Polymyxin B penetrates BBB and cause neurotoxic effect.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q28824 Gene ID: 338037.0 Gene Symbol: MYLK Target Organism: Bos taurus (Bovine) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1847132 |
70.0 µM [IC50] | ||
Target ID: Protein kinase C (Bos taurus) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1847132 |
4.0 µM [IC50] | ||
Target ID: Na,K-ATPase (rat) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1847132 |
800.0 µM [IC50] | ||
Target ID: GO:0043165 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | POLYMYXIN B SULFATE Approved UseAcute infections caused by susceptible strains of Pseudomonas aeruginosa. Launch Date1964 |
|||
Curative | POLYMYXIN B SULFATE Approved UseAcute infections caused by susceptible strains of Pseudomonas aeruginosa. Launch Date1964 |
|||
Curative | POLYMYXIN B SULFATE Approved UseAcute infections caused by susceptible strains of Pseudomonas aeruginosa. Launch Date1964 |
|||
Curative | POLYMYXIN B SULFATE Approved UseAcute infections caused by susceptible strains of Pseudomonas aeruginosa. Launch Date1964 |
PubMed
Title | Date | PubMed |
---|---|---|
LABORATORY AND CLINICAL STUDIES OF POLYMYXIN B AND E. | 1949 Sep |
|
Evolution and dynamics of regulatory architectures controlling polymyxin B resistance in enteric bacteria. | 2008 Oct |
|
Evolution and dynamics of regulatory architectures controlling polymyxin B resistance in enteric bacteria. | 2008 Oct |
|
Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative Bacteria. | 2015 Nov 13 |
|
A feed-forward loop between SroC and MgrR small RNAs modulates the expression of eptB and the susceptibility to polymyxin B in Salmonella Typhimurium. | 2016 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: 25,000 to 30,000 units/kg/day (Intramuscular injection), 50,000 units once daily intrathecally for 3 to 4 days, then 50,000 units once every other day for at least 2 weeks (Intrathecal injection).
15,000 to 25,000 units/kg body weight/day
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1195418/
Polymyxin B MICs were determined for different strains of P. aeruginosa in Ca-MHB using a broth macrodilution method. The MIC was defined as the lowest concentration of drug that resulted in no visible growth after 24 h of incubation at 35°C in ambient air. The polymyxin B MIC ranged from 0.5 to 1 mg/liter.
Substance Class |
Mixture
Created
by
admin
on
Edited
Fri Dec 15 15:51:09 GMT 2023
by
admin
on
Fri Dec 15 15:51:09 GMT 2023
|
Record UNII |
J2VZ07J96K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000007822
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
WHO-VATC |
QA07AA05
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
WHO-VATC |
QS03AA03
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
WHO-VATC |
QS01AA18
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
NDF-RT |
N0000007822
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
WHO-ATC |
S03AA03
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
WHO-ATC |
J01XB02
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
NDF-RT |
N0000007822
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
WHO-VATC |
QJ01XB02
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
NDF-RT |
N0000007822
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
WHO-ATC |
A07AA05
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
CFR |
21 CFR 524.155
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
WHO-ATC |
S02AA11
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
WHO-VATC |
QS02AA11
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
NDF-RT |
N0000175499
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
CFR |
21 CFR 333.120
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
CFR |
21 CFR 524.1484E
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
NDF-RT |
N0000007822
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
CFR |
21 CFR 524.1445
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
CFR |
21 CFR 524.1662B
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
WHO-ATC |
S01AA18
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
CFR |
21 CFR 524.960
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
NCI_THESAURUS |
C78160
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
NDF-RT |
N0000007822
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
CFR |
21 CFR 524.1484H
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
WHO-VATC |
QJ51XB02
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
||
|
CFR |
21 CFR 524.154
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
J2VZ07J96K
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
PRIMARY | |||
|
D011112
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
PRIMARY | |||
|
DTXSID1048467
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
PRIMARY | |||
|
215-768-4
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
PRIMARY | |||
|
POLYMYXIN B
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
PRIMARY | |||
|
SUB03937MIG
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
PRIMARY | |||
|
J2VZ07J96K
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
PRIMARY | |||
|
1404-26-8
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
PRIMARY | |||
|
m8963
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB00781
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
PRIMARY | |||
|
C61894
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
PRIMARY | |||
|
8536
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
PRIMARY | RxNorm | ||
|
4246
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
PRIMARY | |||
|
490
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
PRIMARY | |||
|
Polymyxin B
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201283
Created by
admin on Fri Dec 15 15:51:09 GMT 2023 , Edited by admin on Fri Dec 15 15:51:09 GMT 2023
|
PRIMARY |
All of the following components must be present:
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |